Antipsychotic medication for elderly people with schizophrenia

Area of Science:

• Geriatric Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Schizophrenia affects a growing number of elderly individuals globally.
• Current treatment recommendations for older adults with schizophrenia are often based on data from younger populations.
• There is a lack of clear evidence supporting the appropriateness of current antipsychotic prescribing practices in the elderly.

Purpose of the Study:

• To systematically review and synthesize existing evidence on the efficacy of antipsychotic medications for schizophrenia in individuals aged 65 and older.

Main Methods:

• Conducted a comprehensive search of the Cochrane Schizophrenia Group's Register and relevant trial references.
• Included all clinical randomized trials evaluating antipsychotic drugs for schizophrenia in older adults.
• Extracted and analyzed data using random effects models, calculating relative risks (RR), confidence intervals (CI), and weighted mean differences (WMD).

Main Results:

• Three randomized controlled trials involving 252 elderly participants with schizophrenia were analyzed.
• Limited usable data were available for quality of life, satisfaction, service use, or economic outcomes.
• Results from comparisons of thioridazine vs. remoxipride, risperidone vs. olanzapine, and olanzapine vs. haloperidol showed no significant differences in global state, mental state, or cognitive function.

Conclusions:

• While antipsychotics are commonly used for elderly schizophrenia patients, robust data to guide optimal drug selection are scarce.
• There is an urgent need for large, well-reported randomized controlled trials with relevant outcomes for this demographic.